GAMMA Investing LLC Raises Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV)

GAMMA Investing LLC increased its stake in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 454.0% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 33,539 shares of the company's stock after purchasing an additional 27,485 shares during the period. GAMMA Investing LLC's holdings in Verve Therapeutics were worth $153,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in VERV. Wellington Management Group LLP increased its position in Verve Therapeutics by 4.2% during the fourth quarter. Wellington Management Group LLP now owns 361,498 shares of the company's stock valued at $2,039,000 after acquiring an additional 14,469 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of Verve Therapeutics by 12.5% during the 4th quarter. California State Teachers Retirement System now owns 63,500 shares of the company's stock valued at $358,000 after purchasing an additional 7,046 shares during the period. Public Employees Retirement System of Ohio increased its position in shares of Verve Therapeutics by 81.2% during the 4th quarter. Public Employees Retirement System of Ohio now owns 106,356 shares of the company's stock valued at $600,000 after purchasing an additional 47,656 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Verve Therapeutics by 4.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,818 shares of the company's stock valued at $676,000 after purchasing an additional 4,777 shares during the last quarter. Finally, Vestal Point Capital LP lifted its stake in shares of Verve Therapeutics by 22.9% in the 4th quarter. Vestal Point Capital LP now owns 645,000 shares of the company's stock worth $3,638,000 after purchasing an additional 120,000 shares during the period. Institutional investors own 97.11% of the company's stock.

Verve Therapeutics Stock Performance

VERV traded up $0.04 during trading on Friday, reaching $11.30. 4,134,490 shares of the company traded hands, compared to its average volume of 2,421,004. The company has a market cap of $1.01 billion, a P/E ratio of -5.36 and a beta of 1.67. Verve Therapeutics, Inc. has a 12-month low of $2.86 and a 12-month high of $11.41. The firm has a fifty day simple moving average of $6.02 and a 200 day simple moving average of $6.06.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The company had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million. As a group, sell-side analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VERV. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Guggenheim upped their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. Wall Street Zen raised Verve Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. BMO Capital Markets reissued a "market perform" rating and set a $13.50 price target (down previously from $20.00) on shares of Verve Therapeutics in a report on Friday. Finally, Lifesci Capital downgraded Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 price objective on the stock. in a research note on Wednesday, June 18th. Seven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $14.57.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.